<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04171479</url>
  </required_header>
  <id_info>
    <org_study_id>CLIN-024</org_study_id>
    <nct_id>NCT04171479</nct_id>
  </id_info>
  <brief_title>RMN Versus Manual Epicardial Retrospective PMCF</brief_title>
  <acronym>EPINAV</acronym>
  <official_title>A Retrospective Multicenter Post-Market Clinical Follow-up Registry Comparing Safety and Effectiveness Outcomes of Epicardial Cardiac Ablation Using Remote Navigation to Manual Techniques</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stereotaxis</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Stereotaxis</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Retrospective registry will compare subjects who've undergone a mapping and/or ablation
      procedure for either ischemic ventricular tachycardia or premature ventricular contraction
      using an epicardial approach with either manual or remote magnetic navigation. Subjects will
      be compared with regards to safety, efficacy and mortality.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Up to 10 centers in the European Union will be selected to conduct the trial. Once a site is
      a selected, receives local Ethics Committee approval, and receives Sponsor approval to
      enroll, the site will begin enrollment. All subjects must meet eligibility criteria and
      follow protocol and ethics committee requirements regarding informed consent prior to
      enrollment. Once a subject is enrolled, the site may begin reviewing the subject's medical
      records and entering data into the electronic data capture system. Once enrollment and
      retrospective data entry is complete at a site, a monitoring visit will occur where source
      data verification will occur.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 30, 2020</start_date>
  <completion_date type="Anticipated">November 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">November 30, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Acute Success</measure>
    <time_frame>intra-operative</time_frame>
    <description>Characterize acute success rates for both groups. Acute success for VT procedures is defined as non-inducibility of clinical VT and/or other monomorphic VT at the end of the index-procedure. Acute success for PVC procedures is defined as no recurrence and non-inducibility of culprit PVC at the end of the index-procedure.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Procedural Safety: rates of device-and procedure-related serious adverse events</measure>
    <time_frame>48 hours post index procedure</time_frame>
    <description>Assess rates of device-and procedure-related serious adverse events in both groups.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Chronic Success</measure>
    <time_frame>1 year post index procedure</time_frame>
    <description>Characterize recurrence rates for both groups at 1 year post index procedure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Chronic Safety: rates of device-or procedure-related serious adverse events</measure>
    <time_frame>1 year post index procedure</time_frame>
    <description>Characterize rates of device-or procedure-related serious adverse events for both groups at 1 year post index procedure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>1 year post index procedure</time_frame>
    <description>Assess mortality rate for both groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Chronic Success</measure>
    <time_frame>At last follow up visit, estimated up to 6 years post-procedure for some patients</time_frame>
    <description>Characterize recurrence rates for both groups at last follow up.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Chronic Safety: rates of device-or procedure-related serious adverse events</measure>
    <time_frame>At last follow up visit, estimated up to 6 years post-procedure for some patients</time_frame>
    <description>Characterize rates of device-or procedure-related serious adverse events for both groups at last follow up.</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Ventricular Tachycardia</condition>
  <condition>Premature Ventricular Contraction</condition>
  <arm_group>
    <arm_group_label>Manual</arm_group_label>
    <description>Subjects who underwent epicardial mapping and/or ablation using a manual technique will comprise this group.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Remote Magnetic Navigation</arm_group_label>
    <description>Subjects who underwent epicardial mapping and/or ablation using a remote magnetic technique (using Stereotaxis Niobe system) will comprise this group.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Epicardial mapping and/or ablation</intervention_name>
    <description>Either catheter mapping, ablation, or mapping and ablation will be performed using an epicardial catheter approach.</description>
    <arm_group_label>Manual</arm_group_label>
    <arm_group_label>Remote Magnetic Navigation</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Subjects who have undergone an epicardial cardiac mapping and ablation procedure using
        either manual or remote magnetic (using Stereotaxis Niobe system) guidance.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18 years of age or older

          -  Have undergone an epicardial RF mapping and/or ablation for a ventricular tachycardia
             (VT) as standard of care treatment using either the Niobe MNS or a manual approach

          -  Index procedure was conducted between July 1, 2013-present date.

        Exclusion Criteria:

          -  NA, all subjects who meet inclusion criteria may be enrolled.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_contact>
    <last_name>Ken Lock</last_name>
    <phone>1-314-678-6123</phone>
    <email>ken.lock@stereotaxis.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Na Homolce Hospital</name>
      <address>
        <city>Prague</city>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Petr Neuzil</last_name>
      <email>petr.neuzil@homolka.cz</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Helsinki</name>
      <address>
        <city>Helsinki</city>
        <country>Finland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Pekka Raatikainen</last_name>
      <email>pekka.raatikainen@hus.fi</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>OLVG Hospital</name>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Muchitiar Khan</last_name>
      <email>m.Khan@olvg.nl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Erasmus Medical Center</name>
      <address>
        <city>Rotterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tamas Szili-Torok</last_name>
      <email>t.szilitorok@erasmusms.nl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinical Emergency Hopstial of Bucharest</name>
      <address>
        <city>Bucharest</city>
        <country>Romania</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Radu Vatasescu</last_name>
      <email>radu_vatasescu@yahoo.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Czechia</country>
    <country>Finland</country>
    <country>Netherlands</country>
    <country>Romania</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>April 30, 2019</study_first_submitted>
  <study_first_submitted_qc>November 19, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 21, 2019</study_first_posted>
  <last_update_submitted>March 16, 2020</last_update_submitted>
  <last_update_submitted_qc>March 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tachycardia</mesh_term>
    <mesh_term>Tachycardia, Ventricular</mesh_term>
    <mesh_term>Ventricular Premature Complexes</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

